search
Back to results

Jet Injection for Influenza (JIFI)

Primary Purpose

Influenza, Human

Status
Completed
Phase
Phase 4
Locations
United States
Study Type
Interventional
Intervention
AFLURIA vaccine (2012-2013 formulation)
Needle-Syringe
Stratis needle-free injection device
Sponsored by
PharmaJet, Inc.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Influenza, Human focused on measuring Injections, Jet, Influenza Vaccines

Eligibility Criteria

18 Years - 64 Years (Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Adults aged ≥18 and ≤64 years of age at the time of enrollment
  • Willing and able to give informed consent after reading the consent form and adequate opportunity to discuss the study with the investigator or qualified designee
  • Willing and able to adhere to all protocol required study procedures and to attend scheduled visits.
  • Able to receive the TIV influenza vaccine, based on University of Colorado Health (UCH) employee health flu screening guidelines.
  • Stable health status with no exclusionary medical or neuropsychiatric conditions as determined during the screening evaluation and based on the clinical judgment of the investigator or qualified designee.
  • Access to a consistent means of telephone contact

Exclusion Criteria:

  • Presence of any febrile illness (oral temperature >38°C) on the day of immunization. Such subjects will be reevaluated for enrollment after resolution of illness.
  • Presence of significant acute or chronic uncontrolled medical or neuropsychiatric illness and /or presence of any significant condition that may prohibit inclusion as determined by the investigator or his qualified designee. Uncontrolled is defined as: requiring institution of a new treatment within 1 month prior to study enrollment or change in medication dosage in the month prior to study enrollment.
  • Any immunosuppressive condition including: history of HIV infection, cancer or cancer treatment within 3 years of study enrollment, systemic glucocorticoids (in a dose ≥10 mg prednisone daily or equivalent for more than 7 consecutive days or for 10 or more days in total) within 1 month of study enrollment, or any other cytotoxic or immunosuppressive drug within 3 months of study enrollment. Any significant disorder of coagulation that would increase the risk of intramuscular injections or treatment with Coumadin derivatives or heparin.
  • Known or suspected to be allergic to eggs, chicken protein, gentamicin or influenza vaccine.
  • History of severe or previous serious adverse reaction after an influenza vaccination.
  • Receipt of any immunoglobulin and/or blood products within 3 months of immunization or planned administration of any of these products during the study period.
  • Prior history of any demyelinating disease including Guillain-Barre syndrome.
  • Presence of an active neurological disorder.
  • History of significant alcohol or drug abuse within one year prior to study enrollment.
  • Influenza vaccination or laboratory confirmed influenza infection within the previous six months before study vaccination or planned influenza vaccination during the study period.
  • Planned administration of any non-influenza vaccines 30 days prior to the study or during the study period.
  • Pregnant or plans to become pregnant during the study period.
  • Currently enrolled in another vaccine or drug study.

Sites / Locations

  • Poudre Valley Hospital
  • University of Colorado Health Harmony Campus
  • Medical Center of the Rockies

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

STRATIS Needle-Free

Needle-Syringe

Arm Description

Patients assigned to this arm will receive AFLURIA vaccine administered using the Stratis needle-free injection device.

Patients assigned to this arm will receive AFLURIA vaccine administered using a needle and syringe.

Outcomes

Primary Outcome Measures

Anti Influenza Type A/H1N1 Hemagglutination Inhibition (HAI) Antibody Geometric Mean Titer (GMT)
The GMT criterion for non-inferiority for the upper limit of the 95% CIs of the GMT ratio(GMT with NS / GMT with PJ Stratis) for A/H1N1 antigen will not exceed 1.5 fold.
Anti Influenza Type A/H2N3 Hemagglutination Inhibition (HAI) Antibody Geometric Mean Titer (GMT)
The GMT criterion for non-inferiority for the upper limit of the 95% CIs of the GMT ratio(GMT with NS / GMT with PJ Stratis) for each antigen to not exceed 1.5 fold.
Anti Influenza Type B Hemagglutination Inhibition (HAI) Antibody Geometric Mean Titer (GMT)
The GMT criterion for non-inferiority for the upper limit of the 95% CIs of the GMT ratio(GMT with NS / GMT with PJ Stratis) for each antigen to not exceed 1.5 fold.
Anti Influenza Type A/H1N1 Seroconversion
Seroconversion is defined as a 4-fold rise in HAI titer in post-immunization serum relative to pre-immunization serum, or if pre-immunization serum had an undetectable titer (<1:10), attainment of a post-immunization titer of ≥1:40.
Anti Influenza Type A/H3N2 Seroconversion
Seroconversion is defined as a 4-fold rise in HAI titer in post-immunization serum relative to pre-immunization serum, or if pre-immunization serum had an undetectable titer (<1:10), attainment of a post-immunization titer of ≥1:40.
Anti Influenza Type B Seroconversion
Seroconversion is defined as a 4-fold rise in HAI titer in post-immunization serum relative to pre-immunization serum, or if pre-immunization serum had an undetectable titer (<1:10), attainment of a post-immunization titer of ≥1:40.

Secondary Outcome Measures

Number of Subjects With Complaints Within 30 Minutes Following Vaccination
Number of Subjects With Vaccine Reactogenicity Events
Vaccine reactogenicity will be collected on a patient-completed diary card during checkout from Day 0 and on the next six evenings post-vaccination. The following adverse events will be solicited on the diary card: pain at injection site, tenderness at injection site, redness where the injection is given; induration/swelling (lump) where the injection is given; bruising where the injection is given; itching where the injection is given; headache; tiredness/fatigue (asthenia, lethargy, malaise); general muscle ache (myalgia); chills; nausea; vomiting. Subjects will also record their oral temperature on the diary card each evening.
Number of Subjects With Spontaneously Reported Adverse Events
Subjects will be asked to report any other symptoms experienced in addition to the solicited "immediate" and "vaccine reactogenicity" events. Any other events reported will be tabulated as spontaneously reported adverse events.
Percentage of Subjects Who Received a PJ Stratis Injection Would Choose to Receive This Type of Injection Again

Full Information

First Posted
September 17, 2012
Last Updated
September 29, 2017
Sponsor
PharmaJet, Inc.
search

1. Study Identification

Unique Protocol Identification Number
NCT01688921
Brief Title
Jet Injection for Influenza
Acronym
JIFI
Official Title
Jet Injection for Influenza: A Randomized Controlled Clinical Trial to Demonstrate Non Inferiority of Jet Injection vs. Needle and Syringe for Administration of Trivalent Inactivated Influenza Vaccine
Study Type
Interventional

2. Study Status

Record Verification Date
September 2017
Overall Recruitment Status
Completed
Study Start Date
October 2012 (undefined)
Primary Completion Date
March 2013 (Actual)
Study Completion Date
March 2013 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
PharmaJet, Inc.

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this study is to determine if the administration of a seasonal flu vaccine using a PharmaJet's needle-free injection device (STRATIS) is equivalent to needle and syringe administration, as measured by laboratory tests of immune response.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Influenza, Human
Keywords
Injections, Jet, Influenza Vaccines

7. Study Design

Primary Purpose
Prevention
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
Outcomes Assessor
Allocation
Randomized
Enrollment
1250 (Actual)

8. Arms, Groups, and Interventions

Arm Title
STRATIS Needle-Free
Arm Type
Experimental
Arm Description
Patients assigned to this arm will receive AFLURIA vaccine administered using the Stratis needle-free injection device.
Arm Title
Needle-Syringe
Arm Type
Active Comparator
Arm Description
Patients assigned to this arm will receive AFLURIA vaccine administered using a needle and syringe.
Intervention Type
Biological
Intervention Name(s)
AFLURIA vaccine (2012-2013 formulation)
Other Intervention Name(s)
trivalent inactivated influenza vaccine (TIV), influenza virus vaccine
Intervention Description
Patients will receive a single 0.5 mL injection of AFLURIA vaccine in the deltoid region.
Intervention Type
Device
Intervention Name(s)
Needle-Syringe
Intervention Type
Device
Intervention Name(s)
Stratis needle-free injection device
Primary Outcome Measure Information:
Title
Anti Influenza Type A/H1N1 Hemagglutination Inhibition (HAI) Antibody Geometric Mean Titer (GMT)
Description
The GMT criterion for non-inferiority for the upper limit of the 95% CIs of the GMT ratio(GMT with NS / GMT with PJ Stratis) for A/H1N1 antigen will not exceed 1.5 fold.
Time Frame
28 days
Title
Anti Influenza Type A/H2N3 Hemagglutination Inhibition (HAI) Antibody Geometric Mean Titer (GMT)
Description
The GMT criterion for non-inferiority for the upper limit of the 95% CIs of the GMT ratio(GMT with NS / GMT with PJ Stratis) for each antigen to not exceed 1.5 fold.
Time Frame
28 days
Title
Anti Influenza Type B Hemagglutination Inhibition (HAI) Antibody Geometric Mean Titer (GMT)
Description
The GMT criterion for non-inferiority for the upper limit of the 95% CIs of the GMT ratio(GMT with NS / GMT with PJ Stratis) for each antigen to not exceed 1.5 fold.
Time Frame
28 days
Title
Anti Influenza Type A/H1N1 Seroconversion
Description
Seroconversion is defined as a 4-fold rise in HAI titer in post-immunization serum relative to pre-immunization serum, or if pre-immunization serum had an undetectable titer (<1:10), attainment of a post-immunization titer of ≥1:40.
Time Frame
28 days
Title
Anti Influenza Type A/H3N2 Seroconversion
Description
Seroconversion is defined as a 4-fold rise in HAI titer in post-immunization serum relative to pre-immunization serum, or if pre-immunization serum had an undetectable titer (<1:10), attainment of a post-immunization titer of ≥1:40.
Time Frame
28 days
Title
Anti Influenza Type B Seroconversion
Description
Seroconversion is defined as a 4-fold rise in HAI titer in post-immunization serum relative to pre-immunization serum, or if pre-immunization serum had an undetectable titer (<1:10), attainment of a post-immunization titer of ≥1:40.
Time Frame
28 days
Secondary Outcome Measure Information:
Title
Number of Subjects With Complaints Within 30 Minutes Following Vaccination
Time Frame
Within 30 minutes post-vaccination
Title
Number of Subjects With Vaccine Reactogenicity Events
Description
Vaccine reactogenicity will be collected on a patient-completed diary card during checkout from Day 0 and on the next six evenings post-vaccination. The following adverse events will be solicited on the diary card: pain at injection site, tenderness at injection site, redness where the injection is given; induration/swelling (lump) where the injection is given; bruising where the injection is given; itching where the injection is given; headache; tiredness/fatigue (asthenia, lethargy, malaise); general muscle ache (myalgia); chills; nausea; vomiting. Subjects will also record their oral temperature on the diary card each evening.
Time Frame
Day 0, 1, 2, 3, 4, 5, and 6
Title
Number of Subjects With Spontaneously Reported Adverse Events
Description
Subjects will be asked to report any other symptoms experienced in addition to the solicited "immediate" and "vaccine reactogenicity" events. Any other events reported will be tabulated as spontaneously reported adverse events.
Time Frame
28 days
Title
Percentage of Subjects Who Received a PJ Stratis Injection Would Choose to Receive This Type of Injection Again
Time Frame
28 Days

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
64 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Adults aged ≥18 and ≤64 years of age at the time of enrollment Willing and able to give informed consent after reading the consent form and adequate opportunity to discuss the study with the investigator or qualified designee Willing and able to adhere to all protocol required study procedures and to attend scheduled visits. Able to receive the TIV influenza vaccine, based on University of Colorado Health (UCH) employee health flu screening guidelines. Stable health status with no exclusionary medical or neuropsychiatric conditions as determined during the screening evaluation and based on the clinical judgment of the investigator or qualified designee. Access to a consistent means of telephone contact Exclusion Criteria: Presence of any febrile illness (oral temperature >38°C) on the day of immunization. Such subjects will be reevaluated for enrollment after resolution of illness. Presence of significant acute or chronic uncontrolled medical or neuropsychiatric illness and /or presence of any significant condition that may prohibit inclusion as determined by the investigator or his qualified designee. Uncontrolled is defined as: requiring institution of a new treatment within 1 month prior to study enrollment or change in medication dosage in the month prior to study enrollment. Any immunosuppressive condition including: history of HIV infection, cancer or cancer treatment within 3 years of study enrollment, systemic glucocorticoids (in a dose ≥10 mg prednisone daily or equivalent for more than 7 consecutive days or for 10 or more days in total) within 1 month of study enrollment, or any other cytotoxic or immunosuppressive drug within 3 months of study enrollment. Any significant disorder of coagulation that would increase the risk of intramuscular injections or treatment with Coumadin derivatives or heparin. Known or suspected to be allergic to eggs, chicken protein, gentamicin or influenza vaccine. History of severe or previous serious adverse reaction after an influenza vaccination. Receipt of any immunoglobulin and/or blood products within 3 months of immunization or planned administration of any of these products during the study period. Prior history of any demyelinating disease including Guillain-Barre syndrome. Presence of an active neurological disorder. History of significant alcohol or drug abuse within one year prior to study enrollment. Influenza vaccination or laboratory confirmed influenza infection within the previous six months before study vaccination or planned influenza vaccination during the study period. Planned administration of any non-influenza vaccines 30 days prior to the study or during the study period. Pregnant or plans to become pregnant during the study period. Currently enrolled in another vaccine or drug study.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
David K Cobb, MD, MPH
Organizational Affiliation
Rocky Mountain Infectious Disease Consultants
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Linda McAllister, MD, PhD
Organizational Affiliation
PharmaJet, Inc.
Official's Role
Study Director
Facility Information:
Facility Name
Poudre Valley Hospital
City
Fort Collins
State/Province
Colorado
ZIP/Postal Code
80524
Country
United States
Facility Name
University of Colorado Health Harmony Campus
City
Fort Collins
State/Province
Colorado
ZIP/Postal Code
80528
Country
United States
Facility Name
Medical Center of the Rockies
City
Loveland
State/Province
Colorado
ZIP/Postal Code
80538
Country
United States

12. IPD Sharing Statement

Citations:
PubMed Identifier
24881803
Citation
McAllister L, Anderson J, Werth K, Cho I, Copeland K, Le Cam Bouveret N, Plant D, Mendelman PM, Cobb DK. Needle-free jet injection for administration of influenza vaccine: a randomised non-inferiority trial. Lancet. 2014 Aug 23;384(9944):674-81. doi: 10.1016/S0140-6736(14)60524-9. Epub 2014 May 31.
Results Reference
derived

Learn more about this trial

Jet Injection for Influenza

We'll reach out to this number within 24 hrs